期刊
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
卷 154, 期 4, 页码 558-561出版社
SPRINGER
DOI: 10.1007/s10517-013-1999-2
关键词
amyotrophic lateral sclerosis; gene-cell therapy; SOD1 G93A; transgenic mice; vascular endothelial growth factor; mononuclear umbilical blood cells
资金
- Russian Federation [NSh-4670.2012.4, MK-760.2011.4]
- Ministry of Education and Science [14.740.11.0177, 16.512.11.2101]
Amyotrophic lateral sclerosis is a neurodegenerative disease characterized by progressive death of cerebral and spinal motorneurons. Using behavioral tests we studied the efficiency of gene-cell therapy in SOD1 G93A transgenic mice receiving xenotransplantation of human umbilical cord blood mononuclear cells genetically modified with adenoviral vectors encoding vascular endothelial growth factor (VEGF) and reporter green fluorescent protein (EGFP) genes. The cells were transplanted to mice on week 27 of life (preclinical stage of the disease). Behavioral tests (open field, grip strength test) showed that transplantation of umbilical cord blood mononuclear cells expressing VEGF significantly improved the parameters of motor and explorative activity, grip strength, and animal survival. Thus, gene-cell therapy based on genetically modified mononuclear cells expressing VEGF can be efficient for the treatment of amyotrophic lateral sclerosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据